Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fructanase is an **enzyme** that catalyzes the hydrolysis of fructans (complex polymers of fructose, such as inulin) found in many foods, into simpler sugars more readily absorbed or tolerated by the body[1][3][5][9]. Mechanistically, **fructanase cleaves the terminal (non-reducing) β-(2→1) and β-(2→6) fructosyl linkages of fructans**, thereby reducing the amount of fermentable substrate available to intestinal microbes[1][9]. This action is intended to help prevent gastrointestinal symptoms such as bloating and flatulence that can occur in susceptible individuals, e.g., those with irritable bowel syndrome, after consumption of high-fructan foods[1][5][7]. Fructanase is obtained by fermentation of microorganisms, notably Aspergillus tubingensis, and is used both as a **digestive enzyme supplement for humans** and as a **feed additive in animal nutrition** to improve forage digestion[1][3][5]. It is classified as a GRAS (generally recognized as safe) ingredient for food use in the US[7]. No pharmaceutical drug approval exists; its primary use is as a **dietary supplement** or **food ingredient** to improve tolerance to high-FODMAP (fructan-rich) foods[1][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fructanase.